All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

FDA approval of CD19-targeted ADC, loncastuximab tesirine-Ipyl, for patients with R/R large B-cell lymphoma

May 6, 2021

Bookmark this article

On April 23, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of loncastuximab tesirine-lpyl, an antibody–drug conjugate (ADC), for the treatment of adult patients with relapsed and refractory (R/R) large B-cell lymphoma who have had ≥2 lines of therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high grade B-cell lymphoma.1 This approval was based on the results of the phase II LOTIS-2 trial (NCT03589469), previously reported on the Lymphoma Hub.

Loncastuximab tesirine-Ipyl is a CD19-targeted antibody and alkylating agent conjugate designed to target and kill CD19-expressing malignant B cells. LOTIS-2 is a single-arm, multicenter trial in 145 adult patients with R/R diffuse large B-cell lymphoma (DLBCL) who received ≥2 prior lines of systemic therapy. Treatment with loncastuximab tesirine-Ipyl resulted in an overall response rate of 48.3% and a complete response rate of 24.1%. The median duration of response was 10.3 months. The most common Grade ≥3 treatment-emergent adverse events (in ≥10% of patients) included neutropenia (26.2%), thrombocytopenia (17.9%), increased gamma-glutamyltransferase (17.2%), and anemia (10.3%).

This approval is the first for an CD19-targeted ADC as single-agent therapy for R/R DLBCL.1

On May 5, 2021, loncastuximab tesirine-lpyl was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for the treatment of B-cell lymphomas. As a result, the agent now represents a category 2A treatment option for patients with DLBCL who have relapsed following ≥2 lines of systemic therapy.2

  1. Businesswire.ADC Therapeutics announces FDA approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in relapsed or refractory diffuse large B-cell lymphoma. Published Apr 23, 2021. Accessed Apr 26, 2021.
  2. ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell lymphomas. Published May 5, 2021. Accessed May 7, 2021.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

Which treatment do you select for patients with follicular lymphoma after multiple relapses?
0 votes - 6 days left ...


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox